Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Hydrochlorothiazide and Risk of Skin Cancer
- Conditions
- MelanomaHypertensionNon-melanoma Skin Cancer
- Interventions
- Drug: Angiotensin-converting enzyme (ACE) inhibitors
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 2953748
- Registration Number
- NCT04334824
- Locations
- 🇨🇦
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy
- Conditions
- Renal Function DisorderGlucose Metabolism Disorders
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 30
- Registration Number
- NCT04242758
- Locations
- 🇮🇹
University of Pisa, Pisa, Italy
Generation of Biological Samples Positive to Hydrochlorothiazide for Anti-doping Control
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 3
- Registration Number
- NCT04197622
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03971929
- Locations
- 🇨🇳
The second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Hangzhou, China
Comparison of the Impact of Diet vs Thiazide in BMD in Children With Idiopathic Hypercalciuria
- Conditions
- Hypercalciuria; IdiopathicNephrolithiasis
- Interventions
- Other: Diet for calciuria prevention
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Hospital Infantil de Mexico Federico Gomez
- Target Recruit Count
- 90
- Registration Number
- NCT03951558
- Locations
- 🇲🇽
Children's Hospital of Mexico, Federico Gómez, México, México City, Mexico
Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 84
- Registration Number
- NCT03928145
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.
- Conditions
- HypertensionHyperuricemiaMenopause
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Anna Posadzy-Małaczyńska
- Target Recruit Count
- 180
- Registration Number
- NCT03921736
Protocol of Diuretics Use in Congestive Therapy in Heart Failure
- Conditions
- Heart FailureChronic Heart FailureAcute Heart Failure
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 300
- Registration Number
- NCT03892148
- Locations
- 🇫🇷
Ch Annecy, Annecy, France
🇫🇷CH PUY, Le Puy-en-Velay, France
🇫🇷CHU de GRENOBLE, Grenoble, France
A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT03889145
Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients
- Conditions
- Critical IllnessHypernatremia
- Interventions
- Drug: Placebos
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 184
- Registration Number
- NCT03658850
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.